Cerner Enviza Announces New US FDA Partnership for Drug Safety and Real-World Evidence AI Platform

The US Food and Drug Administration (FDA) has partnered with Cerner Enviza and John Snow Labs to produce artificial intelligence (AI) and machine learning (ML)-based tools to help parse and analyze unstructured real-world data (RWD) and generate real-world evidence related to drug safety. The two-year project will focus on the asthma drug montelukast.

According to Oracle, “Cerner Enviza leverages decades of life sciences expertise spanning commercial, real world, clinical and regulatory research. This includes working with a broad range of Oracle provider networks to help accelerate the discovery, development, and deployment of health insights and therapies. John Snow Labs is known for its AI and NLP in healthcare and is the developer of the Spark NLP library. Together, Cerner Enviza and John Snow Labs will develop a new methodology to enhance computerized queries, or phenotyping, of digital patient data and clinical notes to support pharmacoepidemiology.”

To read more, click here.

(Source: PR Newswire, April 10^th, 2023)